The cost effectiveness of auranofin: results of a randomized clinical trial.
The cost effectiveness of auranofin: results of a randomized clinical trial.
复制标题
金诺芬的成本效益：随机临床试验的结果。
作者：
Thompson Ms;Read Jl;Hutchings Hc;M. Paterson;Harris Ed
在一项为期6个月的随机试验中，在14个地点，金诺芬（AF）治疗类风湿性关节炎患者的成本效益与安慰剂进行了比较。全球健康和对日常生活影响的测量表明，治疗4个月和6个月后，疾病改善的益处超过不良反应（p <0.01），1个月和2个月后安慰剂和治疗患者之间的差异可忽略不计。与AF治疗直接相关的额外医疗费用为每年778美元/患者。观察到的差异，较少的直接医疗费用，得到的帮助，和收入没有统计学意义。
In a 6-month randomized trial at 14 sites, the cost effectiveness of auranofin (AF) treatment for patients with rheumatoid arthritis was gauged in comparison with placebo. Measures of global health and of impacts on daily life suggest that the benefits of disease modification outweigh adverse effects after 4 and 6 months of treatment (p less than 0.01), with negligible differences between placebo and treated patients after 1 and 2 months. Additional medical costs directly associated with AF treatment amounted to $778/patient annually. Observed differences in less direct medical costs, help received, and earnings were not statistically significant.